CIBC Bancorp USA Inc. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

CIBC Bancorp USA Inc. purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, Holdings Channel reports. The firm purchased 18,022 shares of the biopharmaceutical company’s stock, valued at approximately $10,133,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its position in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $226,000. Empowered Funds LLC grew its position in shares of Regeneron Pharmaceuticals by 328.6% during the 2nd quarter. Empowered Funds LLC now owns 9,400 shares of the biopharmaceutical company’s stock worth $4,935,000 after buying an additional 7,207 shares in the last quarter. Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $38,000. Finally, TD Waterhouse Canada Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 16,985.2% in the second quarter. TD Waterhouse Canada Inc. now owns 4,613 shares of the biopharmaceutical company’s stock valued at $2,466,000 after acquiring an additional 4,586 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $732.87 on Friday. The firm has a market cap of $77.48 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The business’s fifty day simple moving average is $765.35 and its 200-day simple moving average is $699.83.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the firm earned $12.07 EPS. Regeneron Pharmaceuticals’s revenue was up 2.5% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on REGN. Canaccord Genuity Group upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Zacks Research downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Finally, Scotiabank lifted their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a report on Monday, November 24th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $802.27.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.